4.63
+0.16(+3.58%)
Currency In USD
| Previous Close | 4.47 |
| Open | 4.47 |
| Day High | 4.66 |
| Day Low | 4.38 |
| 52-Week High | 11.16 |
| 52-Week Low | 3.5 |
| Volume | 703,747 |
| Average Volume | 2.42M |
| Market Cap | 774.98M |
| PE | -1.77 |
| EPS | -2.61 |
| Moving Average 50 Days | 4.54 |
| Moving Average 200 Days | 6.33 |
| Change | 0.16 |
If you invested $1000 in Relay Therapeutics, Inc. (RLAY) since IPO date, it would be worth $132.1 as of February 05, 2025 at a share price of $4.63. Whereas If you bought $1000 worth of Relay Therapeutics, Inc. (RLAY) shares 3 years ago, it would be worth $213.46 as of February 05, 2025 at a share price of $4.63.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Relay Therapeutics to Present at 43rd Annual J.P. Morgan Healthcare Conference
GlobeNewswire Inc.
Jan 07, 2025 9:05 PM GMT
CAMBRIDGE, Mass., Jan. 07, 2025 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies,
Relay Therapeutics Announces Updated Interim Data for RLY-2608 + Fulvestrant Demonstrating Continued Maturation of Clinically Meaningful Progression Free Survival
GlobeNewswire Inc.
Dec 11, 2024 11:00 AM GMT
New interim data show 11.4-month median PFS in 2L patients with PI3Kα-mutated, HR+/HER2- metastatic breast cancer at RP2D 39% confirmed ORR across all patients & 67% in patients with kinase mutations at RP2D Data support planned initiation of 2L pivo
Relay Therapeutics to Present Updated Clinical Data on RLY-2608 in HR+/HER2- Breast Cancer at 2024 San Antonio Breast Cancer Symposium
GlobeNewswire Inc.
Dec 09, 2024 9:05 PM GMT
Company to host conference call on Wednesday, December 11, 2024 at 7am ETCAMBRIDGE, Mass., Dec. 09, 2024 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery proces